OakChart

Imunon Inc

IMNNHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 12:33 PM ET

0.7701+0.0001 (0.01%)
2026-11-11 18:40 CET
Market cap
4.32 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-14.73 USD m
Free cash flow, TTM
-15.18 USD m
EPS diluted, TTM
-3.84
P/E
-
Compare

Price

IMNN against its 20, 50 and 200-day averages
2050200beatearnings
1.002.003.004.001.8M3.5MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26IMNNclose 0.7720-day 0.9650-day 1.19200-day 2.130.7752w high

82.4% under the 52-week high of 4.38 on 14 Nov 2025. 52-week low 0.77 on 10 Nov 2026. Last 15 sessions, 65.6% high to low

Profile

IMNN
52-week range, 0% of the way up
0.774.38

Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm is also engaged in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

Employees20
IPOApr 04, 1994
Beta2.09
ATR, 14d0.10
Rel volume0.57
Short float4.48%
Insider own14.29%
Inst own5.86%

Snapshot

6 groups

Valuation

Index-
Market Cap4.32M
Enterprise Value5.31M
Income-14.73M
Sales0.00M
Book/sh0.90
Cash/sh1.22
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees20
IPOApr 04, 1994

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.86
P/C0.63
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio1.82
Current Ratio1.82
Debt/Eq1.87
LT Debt/Eq1.41
Option/ShortNo / No

Earnings

EPS (ttm)-3.84
EPS next Y-1.82
EPS next Q-0.55
EPS this Y65.42%
EPS next Y22.95%
EPS next 5Y41.53%
EPS past 3/5Y52.95% 44.66%
Sales past 3/5Y- -
EPS Y/Y TTM71.67%
Sales Y/Y TTM-
EPS Q/Q71.00%
Sales Q/Q-
EarningsNov 12 BMO
EPS/Sales Surpr.37.75% -

Ownership

Insider Own14.29%
Insider Trans-2.72%
Inst Own5.86%
Inst Trans-6.66%
ROA-123.77%
ROE-429.72%
ROIC-145.66%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-20.07%
SMA50-35.35%
SMA200-63.79%
Trades-

Technical

Shs Outstand5.61M
Shs Float4.81M
Short Float4.48%
Short Ratio1.90
Short Interest0.22M
52W High4.38 -82.42%
52W Low0.77 0.01%
Volatility11.34% 9.59%
ATR (14)0.10
RSI (14)32.09
Beta2.09
Rel Volume0.57
Avg Volume113.22K
Volume32,981

Performance

Perf Week-15.09%
Perf Month-28.03%
Perf Quarter-51.26%
Perf Half Y-70.38%
Perf YTD-79.79%
Perf Year-80.00%
Perf 3Y-93.79%
Perf 5Y-99.53%
Perf 10Y-99.97%
Recom1.00
Target Price17.00
Prev Close0.77
Price0.77
Change %0.01%

Peers

Mkt cap
TickerCompanyMkt cap
GNPXGenprex Inc1.76M
AIMAIM ImmunoTech Inc6.07M
CLDICalidi Biotherapeutics Inc2.61M
TOVXTheriva Biologics Inc7.19M
ONCYOncolytics Biotech Inc50.44M
PDSBPDS Biotechnology Corp106.03M
GNLXGenelux Corp85.52M
INOInovio Pharmaceuticals Inc139.92M
GOVXGeovax Labs Inc1.26M
SLSSELLAS Life Sciences Group Inc1.72B

Insider trading

6 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Eylward SusanGeneral Counsel and Corp SecAug 31 '26Sale1.562,5253,9502,896Sep 01 04:06 PM
Eylward SusanGeneral Counsel and Corp SecAug 17 '26Sale1.632,4493,9932,896Aug 17 04:17 PM
Eylward SusanGeneral Counsel and Corp SecAug 03 '26Sale1.572,5413,9772,896Aug 04 04:13 PM
Eylward SusanGeneral Counsel and Corp SecJul 20 '26Sale1.782,1503,8302,896Jul 21 04:15 PM
Eylward SusanGeneral Counsel and Corp SecJul 06 '26Sale1.889201,7302,896Jul 07 04:58 PM
Eylward SusanGeneral Counsel and Corp SecJun 29 '26Sale1.7511,80020,6742,896Jun 29 04:34 PM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 206
  • Imunon's Cash Runway, Not Its Quarterly Loss, Defines The Third-Quarter Test (Earnings Whispers) -6.16%
  • IMUNON Presents New Translational Data at SITC 2026 Demonstrating How IMNN-001 Activates and Sustains Anti-Tumor T-Cell Immunity in Advanced Ovarian Cancer (GlobeNewswire)
  • IMUNON to Hold Third Quarter 2026 Financial Results and Business Update Conference Call on Thursday, November 12, 2026 (GlobeNewswire)
  • IMUNON Announces Strategic Sale of ThermoDox (GlobeNewswire) +18.41%
  • IMUNON to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.14%
  • Loading…
  • IMUNON Converts $1.2 Million of Debt-to-Equity (GlobeNewswire)
  • IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan (GlobeNewswire) -8.16%
  • IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review (GlobeNewswire) +5.59%
  • IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001 (GlobeNewswire)
  • IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress (GlobeNewswire)
  • IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001 (GlobeNewswire)
  • IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
  • IMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026 (GlobeNewswire) +5.70%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-12--0.552--0.005
2026Q22026-08-11-0.540-0.868-0.5830.000.004
2026Q12026-05-12-0.840-1.215-0.8450.000.004
2025Q42026-03-31-1.241-1.410-1.2920.000.004
2025Q32025-11-13-1.160-1.199-1.1650.000.003
2025Q22025-08-05-1.870-4.141-1.8660.000.004
2025Q12025-05-12-3.652-4.565-3.6760.000.005
2024Q42025-02-27-3.261-4.670-3.6500.000.005
2024Q32024-11-07-4.435-5.061-4.3750.000.005
2024Q22024-08-14-6.652-7.043-6.6430.000.004
2024Q12024-05-13-6.783-7.392-6.8400.000.003
2023Q42024-03-28-6.522-7.653-6.7830.000.003
2023Q32023-11-14-4.826-8.609-4.8360.000.003
2023Q22023-08-10-7.957-9.196-7.9360.000.002
2023Q12023-05-11-8.870-8.543-8.8060.000.062
2022Q42023-03-30-19.174-11.087-23.2110.130.123

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-150.65-178.53-151.010.500.44
2020FY-131.09-142.83-131.510.500.50
2021FY-49.957-44.348-748.770.500.46
2022FY-65.609-54.304-65.5520.500.50
2023FY-28.174-29.130-28.1410.000.00
2024FY-21.130-21.913-21.1040.000.00
2025FY-6.830-7.127-6.8300.000.00
2026FY--2.362--0.00
2027FY--1.820--0.00
2028FY--1.365--0.00
2029FY--1.205--8.20
2030FY--1.035--24.90

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-122000.000.000.00
2026Q3S2026-08-111000.000.000.00
2026Q3S2026-07-091000.000.000.00
2026Q3S2026-05-122000.000.000.00
2026Q3S2026-04-012000.000.000.00
2026Q3S2026-03-311000.000.000.00
2026Q3S2025-11-131000.000.000.00
2026Q3S2025-11-111000.000.000.00
2026Q3S2025-11-101000.000.000.00
2026Q3S2025-11-091000.000.000.00
2026Q3S2025-11-081000.000.000.00
2026Q3S2025-11-071000.000.000.00
2026Q3S2025-11-061000.000.000.00
2026Q3S2025-11-051000.000.000.00

Estimate history

EPS, annual-532.221-132.232-151.012-131.513-748.772-65.552-28.141-21.104-6.827-3.8428
Period201720182019202020212022202320242025TTM
EPS, quarterly-6.643-4.375-3.65-3.676-1.866-1.165-1.292-0.845-0.541
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0.50.50.50.50.50.50000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.0880.0960.1190.2080.0290.570.7211.1123.424.666
Period201720182019202020212022202320242025MRQ
Shares, quarterly0.7211.1121.1121.1211.9752.8963.423.9234.666
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.500.500.500.500.50
Cost of Goods Sold Incl. D&A0.670.700.720.720.730.70---
Gross Profit-0.67-0.70-0.72-0.72-0.23-0.20---
Selling, General and Administrative Excl. Other14.1613.9518.4120.3124.6920.8018.2420.3421.21
Research and Development8.197.7811.6411.2911.7310.6211.3413.0711.87
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-14.84-14.65-19.13-21.03-24.92-21.01-18.49-20.57-21.07
Interest Expense0.080.000.000.205.030.571.291.390.71
Unusual Expense-0.020.000.000.337.970.593.67-2.790.89
Net Income Before Taxes-14.72-14.50-18.62-20.80-37.47-22.15-23.33-18.67-22.30
Income Taxes0.000.000.00-1.28-1.57-1.38-1.85-1.82-10.42
Consolidated Net Income-14.72-14.50-18.62-19.51-35.90-20.77-21.48-16.85-11.88
Net Income From Continuing Operations-14.72-14.50-18.62-19.51-35.90-20.77-21.48-16.85-11.88
Net Income-14.73-14.50-18.62-19.51-35.90-20.77-21.48-16.85-11.88
EPS (Recurring)-2.82-6.83-21.10-27.81-55.36-733.92-115.78-168.51-125.30
EPS (Basic, Before Extraordinaries)-3.84-6.83-21.10-28.14-65.55-748.77-131.51-151.01-132.23
EPS (Diluted)-3.84-6.83-21.10-28.14-65.55-748.77-131.51-151.01-132.23
EBITDA-14.16-13.95-18.41-20.31-24.19-20.30-17.74-19.84-20.71
Non-Operating Income (Expense)0.180.160.510.760.460.010.120.500.36
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.650.130.500.802.132.771.391.683.64
Price To Sales Ratio----19.295.8645.4574.6749.58
Gross Margin-----46.33-40.58---
Operating Margin-----4,984.31-4,201.44-3,697.28-4,113.09-4,213.01
Net Margin-----7,179.65-4,153.85-4,296.71-3,370.31-2,376.67
Shares Outstanding4.673.421.110.720.570.030.210.120.10
Market Capitalization4.324.3213.786.379.583.1228.9439.7726.55

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.170.170.170.170.160.200.170.19
Gross Profit-0.17-0.17-0.17-0.17-0.16-0.20-0.17-0.19
Selling, General and Administrative Excl. Other2.624.144.093.312.603.953.984.77
Research and Development1.462.342.491.901.232.172.233.29
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.79-4.31-4.26-3.48-2.77-4.15-4.15-4.96
Interest Expense0.080.000.000.000.000.000.000.00
Unusual Expense-0.020.000.000.000.000.000.000.00
Net Income Before Taxes-2.81-4.25-4.22-3.43-2.74-4.10-4.06-4.85
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-2.81-4.25-4.22-3.43-2.74-4.10-4.06-4.85
Net Income From Continuing Operations-2.81-4.25-4.22-3.43-2.74-4.10-4.06-4.85
Net Income-2.83-4.25-4.22-3.43-2.74-4.10-4.06-4.85
EPS (Recurring)-0.54-0.84-1.29-1.16-1.87-3.68-3.65-4.38
EPS (Basic, Before Extraordinaries)-0.54-0.84-1.29-1.16-1.87-3.68-3.65-4.38
EPS (Diluted)-0.54-0.84-1.29-1.16-1.87-3.68-3.65-4.38
EBITDA-2.62-4.14-4.09-3.31-2.60-3.95-3.98-4.77
Non-Operating Income (Expense)0.030.060.040.050.030.040.090.12
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.090.550.010.000.100.200.140.23
Shares Outstanding4.673.923.422.901.981.121.111.11
Market Capitalization4.3210.0011.7012.9320.6115.3513.7815.37

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments8.785.8715.7034.2549.3917.1614.8627.6124.17
Short Term Receivables0.000.000.000.130.110.000.020.070.05
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets1.942.142.552.782.451.661.350.450.09
Total Current Assets10.728.0118.2437.1551.9518.8216.2428.1324.31
Net Property, Plant & Equipment1.511.662.350.701.171.341.840.180.18
Total Investments and Advances0.000.000.004.506.000.000.000.000.00
Intangible Assets---0.0013.3715.4618.0518.2823.02
Deferred Tax Assets-0.001.281.571.381.851.82--
Other Assets0.050.050.050.050.180.060.330.260.01
Total Assets12.299.7221.9243.9874.0537.5338.2846.8647.51
Short Term Debt Incl. Current Port. of LT Debt0.410.450.491.660.551.552.230.000.00
Accounts Payable1.391.303.523.592.552.242.863.023.42
Other Current Liabilities2.823.033.394.793.672.962.803.092.78
Total Current Liabilities4.624.797.3910.046.776.757.896.116.20
Long Term Debt0.600.691.144.616.094.649.119.420.00
Provision for Risks Charges0.000.000.000.005.407.025.728.9112.54
Other Liabilities0.000.000.000.000.000.501.001.562.07
Total Liabilities5.235.478.5314.6518.2518.9223.7225.9920.81
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity7.064.2413.3929.3355.8018.6114.5620.8626.70
Total Shareholders Equity7.064.2413.3929.3355.8018.6114.5620.8626.70
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity7.064.2413.3929.3355.8018.6114.5620.8626.70
Total Liabilities & Stockholders Equity12.299.7221.9243.9874.0537.5338.2846.8647.51
Book Value Per Share2.073.8218.5851.441,891.7989.46122.49216.73302.41
Tangible Book Value Per Share2.073.8218.5851.441,438.6015.17-29.4026.8141.75
Full-Time Employees202533312927292921
Price to Book Ratio0.863.250.350.230.061.552.731.274.24
Return on Assets-131.74-117.72-59.23-60.83-37.23-56.68-39.59-25.18-52.95
Return on Equity-256.41-211.21-91.37-84.34-55.83-129.54-95.15-49.97-124.13
Return on Invested Capital-189.12-377.60-134.34-105.77-33.56-92.38-71.21-39.25-77.69
Quick Ratio2.321.672.473.707.672.792.064.613.92
Current Ratio2.321.672.473.707.672.792.064.613.92

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-14.72-14.50-18.62-19.51-35.90-20.77-21.48-16.85-11.88
Depreciation0.670.700.720.720.730.700.740.720.36
Other Funds (Non Cash)1.030.230.421.5510.824.356.01-0.115.70
Funds from Operations-13.01-13.57-16.21-16.96-24.34-15.25-14.75-18.06-5.82
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-2.10-0.33-2.65-2.071.21-0.97-0.86-2.20-1.22
Cash from Operating Activities-15.11-13.90-18.85-19.02-23.13-16.22-15.62-20.26-7.04
Capital Expenditures-0.07-0.28-0.03-0.45-0.27-0.31-0.02-0.35-0.14
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments0.000.009.8611.468.58-29.817.946.29-1.49
Purchase of Investments0.000.00-0.06-13.54-48.19-53.81-9.96-23.83-16.97
Sale Or Maturity of Investments0.000.009.9225.0056.7724.0017.9030.1115.48
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.07-0.289.8311.018.32-30.127.925.94-1.63
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock15.2817.099.062.786.7254.2023.187.840.86
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock15.2817.099.062.786.7254.2023.187.840.86
Proceedsfrom Stock Options13.7813.629.062.786.7254.2022.817.840.86
Issuance or Reduction of Debt, Net7.030.000.000.000.000.57-5.200.009.72
Change in Long Term Debt7.030.000.000.000.000.57-5.200.009.72
Issuance of Long Term Debt7.030.000.000.000.005.761.320.009.72
Reduction of Long Term Debt0.000.000.000.000.00-5.19-6.520.000.00
Net Financing Active Other Cash Flow-0.000.000.00-6.420.000.000.000.000.00
Other Financing Activities Uses-0.000.000.00-6.420.000.000.000.000.00
Cash from Financing Activities22.3217.099.06-3.646.7254.7717.987.8410.58
Net Change in Cash7.142.910.03-11.65-8.098.4210.29-6.481.91
Free Cash Flow-15.18-14.18-18.88-19.47-23.40-16.54-15.64-20.61-7.18
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.001.280.290.000.46-0.03-1.820.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments6.864.798.785.254.732.87
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets1.831.831.942.012.162.22
Total Current Assets8.696.6210.727.266.895.09
Net Property, Plant & Equipment1.251.351.511.681.851.72
Total Investments and Advances5.000.000.000.000.000.00
Other Assets0.050.050.050.050.050.05
Total Assets14.998.0212.298.998.796.86
Short Term Debt Incl. Current Port. of LT Debt1.930.420.410.390.380.39
Accounts Payable1.620.961.391.131.741.86
Other Current Liabilities1.232.782.822.683.203.54
Total Current Liabilities4.784.174.624.205.325.80
Long Term Debt5.910.490.600.710.810.61
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.110.000.000.000.000.00
Total Liabilities10.804.665.234.916.136.41
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value3E-060.000.000.000.000.00
Common Equity4.193.367.064.082.660.45
Total Shareholders Equity4.193.367.064.082.660.45
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity4.193.367.064.082.660.45
Total Liabilities & Stockholders Equity14.998.0212.298.998.796.86
Book Value Per Share0.900.862.071.411.350.40
Tangible Book Value Per Share0.900.862.071.411.350.40
Full-Time Employees--20---
Price to Book Ratio0.861.422.703.817.7533.96
Return on Assets-123.77-196.78-131.74-122.58-170.41-167.96
Return on Equity-429.72-768.25-256.41-233.50-491.97-397.54
Return on Invested Capital-27.86-110.29-55.10-71.59-78.95-385.14
Quick Ratio1.821.592.321.731.300.88
Current Ratio1.821.592.321.731.300.88

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-2.81-4.25-4.22-3.43-2.74-4.10
Depreciation0.170.170.170.170.160.20
Other Funds (Non Cash)0.580.550.01-0.110.120.20
Funds from Operations-2.06-3.53-4.04-3.37-2.45-3.70
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.97-0.450.38-1.07-0.500.85
Cash from Operating Activities-3.03-3.99-3.66-4.44-2.95-2.85
Capital Expenditures-0.070.00-0.000.00-0.02-0.26
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.070.00-0.000.00-0.02-0.26
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.00
Change in Capital Stock3.130.007.194.964.830.11
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock3.130.007.194.964.830.11
Proceedsfrom Stock Options3.130.007.193.462.860.11
Issuance or Reduction of Debt, Net7.030.000.000.000.000.00
Change in Long Term Debt7.030.000.000.000.000.00
Issuance of Long Term Debt7.030.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.00-0.000.000.000.000.00
Other Financing Activities Uses0.00-0.000.000.000.000.00
Cash from Financing Activities10.16-0.007.194.964.830.11
Net Change in Cash7.07-3.993.530.521.86-3.00
Free Cash Flow-3.09-3.99-3.66-4.44-2.97-3.11

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-304.48%0.2M4.8M108.40K
2026-10-151.30%0.1M4.8M158.11K
2026-09-303.58%0.2M4.8M149.51K
2026-09-153.97%0.2M4.9M142.48K
2026-08-311.84%0.1M4.9M124.47K
2026-08-142.28%0.1M5.0M124.71K
2026-07-314.02%0.2M3.7M124.47K
2026-07-150.48%0.0M3.8M52.15K
2026-06-301.33%0.1M3.8M52.92K
2026-06-151.89%0.1M4.1M98.45K
2026-05-291.43%0.1M4.0M93.81K
2026-05-153.59%0.1M4.1M87.70K
2026-04-304.10%0.2M3.8M89.07K
2026-04-153.73%0.1M3.8M89.76K
2026-03-314.91%0.2M3.8M94.34K
2026-03-136.31%0.2M3.3M45.52K
2026-02-276.50%0.2M3.3M48.32K
2026-02-137.10%0.2M3.3M49.58K
2026-01-307.72%0.3M3.3M54.19K
2026-01-157.61%0.3M3.3M61.75K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-104Statement of changes in beneficial ownership of securities2026-11-06SEC
2026-11-104Statement of changes in beneficial ownership of securities2026-11-06SEC
2026-11-104Statement of changes in beneficial ownership of securities2026-11-06SEC
2026-11-104Statement of changes in beneficial ownership of securities2026-11-06SEC
2026-11-104Statement of changes in beneficial ownership of securities2026-11-06SEC
2026-11-104Statement of changes in beneficial ownership of securities2026-11-06SEC
2026-11-104Statement of changes in beneficial ownership of securities2026-11-06SEC
2026-10-28S-1/ASEC
2026-10-27S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-10-278-KCurrent report2026-10-26SEC
2026-10-218-KCurrent report2026-10-20SEC
2026-10-13DRSSEC
2026-10-134Statement of changes in beneficial ownership of securities2026-10-09SEC
2026-10-134Statement of changes in beneficial ownership of securities2026-10-09SEC
2026-10-134Statement of changes in beneficial ownership of securities2026-10-09SEC
2026-09-298-KCurrent report2026-09-28SEC
2026-09-284Statement of changes in beneficial ownership of securities2026-09-25SEC
2026-09-284Statement of changes in beneficial ownership of securities2026-09-25SEC
2026-09-284Statement of changes in beneficial ownership of securities2026-09-25SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-014Statement of changes in beneficial ownership of securities2026-08-28SEC
2026-09-014Statement of changes in beneficial ownership of securities2026-08-28SEC
2026-09-014Statement of changes in beneficial ownership of securities2026-08-28SEC
2026-09-014Statement of changes in beneficial ownership of securities2026-08-28SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-14SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080011.92K3
2026-07005.56K2
2026-060020.67K1
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
ARMISTICE CAPITAL, LLC3.45%
VANGUARD CAPITAL MANAGEMENT LLC1.12%
Riverview Capital Advisers, LLC0.82%
GEODE CAPITAL MANAGEMENT, LLC0.73%
Virtu Financial LLC0.42%
VANGUARD FIDUCIARY TRUST CO0.32%
NORTHERN TRUST CORP0.25%
BlackRock, Inc.0.11%
Tower Research Capital LLC0.09%
WELLS FARGO & COMPANY/MN0.08%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND1.12%
Fidelity Extended Market Index Fund0.58%
Fidelity Series Total Market Index Fund0.08%
Fidelity Total Market Index Fund0.03%
Fidelity Nasdaq Composite Index Fund0.00%

OakChart. IMNN. Cached 15 minutes.

Some panels did not load: ratings.